Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Alkermes Plc before investing.

In this article, we go over a few key elements for understanding Alkermes Plc’s stock price such as:

• Alkermes Plc’s current stock price and volume
• Why Alkermes Plc’s stock price changed recently
• Upgrades and downgrades for ALKS from analysts
• ALKS’s stock price momentum as measured by its relative strength

About Alkermes Plc (ALKS)

Before we jump into Alkermes Plc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Want to learn more about Alkermes Plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Alkermes Plc.

Alkermes Plc’s Stock Price as of Market Close

As of July 25, 2024, 4:00 PM, CST, Alkermes Plc’s stock price was $28.04.

Alkermes Plc is up 5.77% from its previous closing price of $26.51.

During the last market session, Alkermes Plc’s stock traded between $25.63 and $27.44. Currently, there are 168.32 million shares of Alkermes Plc stock available for purchase.

Alkermes Plc’s price-earnings (P/E) ratio is currently at 7.6, which is low compared to the Biotechnology & Medical Research industry median of 27.9. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Alkermes Plc Stock Price History

Alkermes Plc’s (ALKS) price is currently up 16.35% so far this month.

During the month of July, Alkermes Plc’s stock price has reached a high of $28.18 and a low of $22.90.

Over the last year, Alkermes Plc has hit prices as high as $32.88 and as low as $22.01. Year to date, Alkermes Plc’s stock is up 7.31%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Alkermes Plc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 24, 2024, there were 3 analysts who downgraded Alkermes Plc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Alkermes Plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Alkermes Plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Alkermes Plc’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Alkermes Plc (ALKS) by visiting AAII Stock Evaluator.

Relative Price Strength of Alkermes Plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 24, 2024, Alkermes Plc has a weighted four-quarter relative price strength of -5.90%, which translates to a Momentum Score of 42 and is considered to be Average.

Want to learn more about how Alkermes Plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Alkermes Plc Stock Price: Bottom Line

As of July 25, 2024, Alkermes Plc’s stock price is $28.04, which is up 5.77% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Alkermes Plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.